Dainippon Sumitomo To Conduct Trials Outside Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma became the latest drug maker to announce it would shift some of its clinical trials to other Asian nations. Dainippon said that among the drugs being developed for the Japanese market is its antipsychotic treatment lurasidone, which is to undergo Phase III tests in South Korea and Taiwan. The move was made possible after Japan's health ministry indicated it would acknowledge foreign trials if they include at least some Japanese patients. Dainippon said future trials abroad would be held in areas where the people are similar physically to Japanese. (Click here for more - a subscription may be required